Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H1 2015

Transcription

1 Brochure More information from Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H Description: Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H Summary This, Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H1 2015, provides an overview of the Relapsing Remitting Multiple Sclerosis (RRMS) s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS) and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in -class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Relapsing Remitting Multiple Sclerosis (RRMS) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Relapsing Remitting Multiple Sclerosis (RRMS) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Relapsing Remitting Multiple Sclerosis (RRMS) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Relapsing Remitting Multiple Sclerosis (RRMS) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies

2 - Identify and understand important and diverse types of therapeutics under development for Relapsing Remitting Multiple Sclerosis (RRMS) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Relapsing Remitting Multiple Sclerosis (RRMS) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Contents: List of Tables List of Figures Introduction REPORT COVERAGE Relapsing Remitting Multiple Sclerosis (RRMS) Overview Therapeutics Development Pipeline Products for Relapsing Remitting Multiple Sclerosis (RRMS) - Overview Pipeline Products for Relapsing Remitting Multiple Sclerosis (RRMS) - Comparative Analysis Relapsing Remitting Multiple Sclerosis (RRMS) - Therapeutics under Development by Companies Relapsing Remitting Multiple Sclerosis (RRMS) - Therapeutics under Investigation by Universities/Institutes Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Products Glance Late Stage Products Clinical Stage Products Early Stage Products Relapsing Remitting Multiple Sclerosis (RRMS) - Products under Development by Companies Relapsing Remitting Multiple Sclerosis (RRMS) - Products under Investigation by Universities/Institutes Relapsing Remitting Multiple Sclerosis (RRMS) - Companies Involved in Therapeutics Development AbbVie Inc. Actelion Ltd Allozyne, Inc. Amarna Therapeutics B.V. Antisense Therapeutics Limited Biogen, Inc. Cognosci, Inc. F. Hoffmann-La Roche Ltd. Forward Pharma A/S Genmab A/S GlaxoSmithKline plc Iltoo Pharma Mapi Pharma Ltd. MedImmune, LLC Merck KGaA Mitsubishi Tanabe Pharma Corporation Neurotec Pharma SL Novartis AG Nuron Biotech, Inc. Octapharma AG Opexa Therapeutics, Inc. RedHill Biopharma Ltd. Sanofi Synthetic Biologics, Inc. Teva Pharmaceutical Industries Limited XenoPort, Inc. Zydus Cadila Healthcare Limited Relapsing Remitting Multiple Sclerosis (RRMS) - Therapeutics Assessment Assessment by Monotherapy Products Assessment by Combination Products Assessment by Target Assessment by Assessment by Route of Administration Assessment by Molecule Type Drug Profiles

3 (rifabutin + clarithromycin + clofazimine) - Drug Profile aldesleukin - Drug Profile ATL Drug Profile ATXMS Drug Profile AZ-17 - Drug Profile Cell Therapy for Relapsing Remitting Multiple Sclerosis - Drug Profile COG Drug Profile daclizumab - Drug Profile diazoxide - Drug Profile dimethyl fumarate - Drug Profile estriol - Drug Profile Gene Therapy for Relapsing and Remitting Multiple Sclerosis - Drug Profile glatiramer acetate ER - Drug Profile GSK Drug Profile Guanabenz - Drug Profile HR Drug Profile

4 hydralazine - Drug Profile imilecleucel-t - Drug Profile immune globulin (human) - Drug Profile interferon beta-1b - Drug Profile interferon beta-1b - Drug Profile interferon beta-1b - Drug Profile laquinimod sodium - Drug Profile MEDI Drug Profile MT Drug Profile ofatumumab - Drug Profile olesoxime - Drug Profile opicinumab - Drug Profile Pegylated Interferon-Beta-1b - Drug Profile ponesimod - Drug Profile siponimod - Drug Profile Small Molecule to Target CTLA4 and IFNGR for RRMS - Drug Profile

5 vatelizumab - Drug Profile VAY Drug Profile XP Drug Profile Relapsing Remitting Multiple Sclerosis (RRMS) - Recent Pipeline Updates Relapsing Remitting Multiple Sclerosis (RRMS) - Dormant Projects Relapsing Remitting Multiple Sclerosis (RRMS) - Discontinued Products Relapsing Remitting Multiple Sclerosis (RRMS) - Product Development Milestones Featured News & Press Releases Feb 26, 2015: Abbvie's Ongoing Research In Neuroscience And Oncology On ZINBRYTA Will Be Featured At The 2015 American Academy Of Neurology Annual Meeting Dec 17, 2014: First Patient Treated in Mapi Pharma's Phase IIa Clinical Trial of GA Depot for Relapsing Remitting Multiple Sclerosis Nov 04, 2014: Genzyme Announces Enrollment of First Patient in Phase II Vatelizumab Trial in Relapsing Remitting Multiple Sclerosis Sep 12, 2014: Detailed Results from Biogen Idec and AbbVie s Pivotal Phase 3 Decide Study Further Define the Efficacy and Safety Profile of ZINBRYTA (Daclizumab High-Yield Process) Sep 12, 2014: Teva Presents New Clinical Safety Data in RRMS Patients Treated with Laquinimod for Two or More Years at Joint ACTRIMS-ECTRIMS Meeting Jul 31, 2014: Expanded Data on Disability and Cognitive Improvements in Phase II Study of Synthetic Biologics' Trimesta in Multiple Sclerosis to be Presented at 2014 Joint ACTRIMS-ECTRIMS Meeting May 30, 2014: Genmab Announces Ofatumumab Development Plans in RRMS and NMO May 23, 2014: Teva and Active Biotech to Continue with the Development of Nerventra for Multiple Sclerosis Following Confirmation of CHMP Opinion Apr 29, 2014: Synthetic Biologics Reports University of California, Los Angeles Announcement Of Preliminary Positive Topline Efficacy And Safety Results From Investigator-Led Phase 2 Study Of Trimesta For Relapsing- Remitting Multiple Sclerosis Apr 07, 2014: ATL1102 for MS - US Patent Allowance Extends Strong IP Position Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer List of Tables Number of Products under Development for Relapsing Remitting Multiple Sclerosis (RRMS), H Number of Products under Development for Relapsing Remitting Multiple Sclerosis (RRMS) - Comparative Analysis, H Number of Products under Development by Companies, H Number of Products under Development by Companies, H (Contd..1) Number of Products under Development by Companies, H (Contd..2) Number of Products under Investigation by Universities/Institutes, H Comparative Analysis by Late Stage Development, H Comparative Analysis by Clinical Stage Development, H Comparative Analysis by Early Stage Development, H Products under Development by Companies, H Products under Development by Companies, H (Contd..1) Products under Development by Companies, H (Contd..2) Products under Investigation by Universities/Institutes, H Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by AbbVie Inc., H1 2015

6 Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Actelion Ltd, H Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Allozyne, Inc., H Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Amarna Therapeutics B.V., H Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Antisense Therapeutics Limited, H Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Biogen, Inc., H Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Cognosci, Inc., H Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by F. Hoffmann-La Roche Ltd., H Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Forward Pharma A/S, H Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Genmab A/S, H Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by GlaxoSmithKline plc, H Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Iltoo Pharma, H Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Mapi Pharma Ltd., H Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by MedImmune, LLC, H Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Merck KGaA, H Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Mitsubishi Tanabe Pharma Corporation, H Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Neurotec Pharma SL, H Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Novartis AG, H Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Nuron Biotech, Inc., H Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Octapharma AG, H Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Opexa Therapeutics, Inc., H Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by RedHill Biopharma Ltd., H Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Sanofi, H Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Synthetic Biologics, Inc., H Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Teva Pharmaceutical Industries Limited, H Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by XenoPort, Inc., H Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Zydus Cadila Healthcare Limited, H Assessment by Monotherapy Products, H Assessment by Combination Products, H Number of Products by Stage and Target, H Number of Products by Stage and, H Number of Products by Stage and Route of Administration, H Number of Products by Stage and Molecule Type, H Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics - Recent Pipeline Updates, H Relapsing Remitting Multiple Sclerosis (RRMS) - Dormant Projects, H Relapsing Remitting Multiple Sclerosis (RRMS) - Dormant Projects (Contd..1), H Relapsing Remitting Multiple Sclerosis (RRMS) - Dormant Projects (Contd..2), H Relapsing Remitting Multiple Sclerosis (RRMS) - Discontinued Products, H Relapsing Remitting Multiple Sclerosis (RRMS) - Discontinued Products (Contd..1), H List of Figures Number of Products under Development for Relapsing Remitting Multiple Sclerosis (RRMS), H Number of Products under Development for Relapsing Remitting Multiple Sclerosis (RRMS) - Comparative Analysis, H Number of Products under Development by Companies, H Number of Products under Investigation by Universities/Institutes, H Comparative Analysis by Late Stage Development, H Comparative Analysis by Clinical Stage Development, H Assessment by Monotherapy Products, H Number of Products by Top 10 Targets, H Number of Products by Stage and Top 10 Targets, H Number of Products by Top 10 s, H Number of Products by Stage and Top 10 s, H Number of Products by Top 10 Routes of Administration, H Number of Products by Stage and Top 10 Routes of Administration, H Number of Products by Top 10 Molecule Types, H Number of Products by Stage and Top 10 Molecule Types, H Ordering: Order Online - Order by Fax - using the form below

7 Order by Post - print the order form below and send to Research and Markets, Guinness Centre, Taylors Lane, Dublin 8, Ireland.

8 Page 1 of 2 Fax Order Form To place an order via fax simply print this form, fill in the information below and fax the completed form to (from USA) or (from Rest of World). If you have any questions please visit Order Information Please verify that the product information is correct and select the format(s) you require. Product Name: Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H Web Address: Office Code: Product Formats Please select the product formats and quantity you require: SC Electronic (PDF) - Single User: Electronic (PDF) - Site License: Electronic (PDF) - Enterprisewide: Quantity USD 2000 USD 4000 USD 6000 Contact Information Please enter all the information below in BLOCK CAPITALS Title: Mr Mrs Dr Miss Ms Prof First Name: Last Name: Address: * Job Title: Organisation: Address: City: Postal / Zip Code: Country: Phone Number: Fax Number: * Please refrain from using free accounts when ordering (e.g. Yahoo, Hotmail, AOL)

9 Page 2 of 2 Payment Information Please indicate the payment method you would like to use by selecting the appropriate box. Pay by credit card: You will receive an with a link to a secure webpage to enter your credit card details. Pay by check: Please post the check, accompanied by this form, to: Research and Markets, Guinness Center, Taylors Lane, Dublin 8, Ireland. Pay by wire transfer: Please transfer funds to: Account number Sort code Swift code IBAN number Bank Address ULSBIE2D IE78ULSB Ulster Bank, Main Street, Blackrock, Co. Dublin, Ireland. If you have a Marketing Code please enter it below: Marketing Code: Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at Please fax this form to: (646) or (646) From USA or From Rest of World